Pharmaceutical Continuous Manufacturing Market Growth by 2027

Pharmaceutical Continuous Manufacturing Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product (Integrated Systems, Semi-Continuous Systems, Controls); Application (End Product Manufacturing, API Manufacturing); End User (Full-Scale Manufacturing Companies, R&D Departments) and Geography

Publication Month : Apr 2020

  • Report Code : TIPRE00008245
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 239
Inquire Before Buy

PRICING

$4550

$2730

The pharmaceutical continuous manufacturing market is expected to reach US$ 3,064.38 million by 2027 from US$ 1,459.53 million in 2019. The market is estimated to grow at a CAGR of 9.8% from 2020 to 2027.

Continuous manufacturing in the pharmaceuticals industry is a result of advancements in technology with respect to the production techniques. In the past years, the traditional method of batch manufacturing was followed in the pharmaceuticals industry. However, the development in technology has accelerated mass production with improved quality, and it has addressed many primary issues such as the recall of drugs. The pharmaceuticals industry has recently begun to acknowledge the continuous manufacturing as an option to improve and sustain manufacturing operations.

Lucrative Regions forPharmaceutical Continuous ManufacturingMarkets



Lucrative Regions forPharmaceutical Continuous ManufacturingMarkets
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Market Insights

Increasing Shortage of Medicines

Shortages of essential medicines and drugs are becoming increasingly frequent worldwide. The rising shortage is resulting in burden on the health systems along with additional costs as well as risk to the patients’ health. The patients in need of medicines are failing to receive appropriate doses due to unavailability of medicines. According to WHO Drug Information 2016, shortages of essential medicines have been reported from low, middle, and high-income countries. Medicines shortages pose risks for patient health as a result of non-treatment, under-treatment and possible medication errors from attempts to substitute missing medicines.

The Food and Drug Administration (FDA) states that the reasons for drug shortages occur for various reasons including quality problems, manufacturing inefficiency, delays, and discontinuations. The drugs that are often short in supply include sterile injectable and oncology/cancer treatments. The notice from manufacturers to the FDA regarding the impending or current shortages of drugs allows the FDA to work with the manufacturers over finding feasible solutions, one of which is usually ramping up the manufacturing of drugs through implementation of new and advanced systems such as continuous manufacturing.

In 2018, the US FDA developed a new Drug Shortage Task Force to explore the reasons and causes of drug shortages. The Task Force analyzed 163 drugs that went short in supply from 2013 to 2017. Moreover, a survey from The Institute for Safe Medication Practices (ISMP) in 2017 revealed that the treatment category was most commonly involved in drug shortages.

The scenario of drug shortage is also prevalent in the European countries. For instance, according to a report published by The Economist Intelligence Unit Limited in 2017, the prevalence of medicine shortage was highin Europe. The three major causes determined for the shortage included manufacturing, economic and regulatory causes. Thus, to meet the rising demand for biologics and drugs and to curb the lack of drug availability, pharmaceutical continuous manufacturing market holds a promising growth scenario.

Product-BasedInsights

In 2019, the integrated systems segment accounted for the largest market share ofthe global pharmaceutical continuous manufacturing market. The integrated systems are expected to dominate the product segment owing to their easy availability and accessibility as well as higher adoption of these systems than the semi-continuous systems and the controls. The integrated systems help build the continuous flow during manufacturing process, facilitate end-to-end integration, and improve asset utilization.

Global Pharmaceutical Continuous Manufacturing Market, by Product– 2019 & 2027



Global Pharmaceutical Continuous Manufacturing Market, by Product– 2019 & 2027
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Application-BasedInsights

Based on application, the pharmaceutical continuous manufacturing market is segmented into end product manufacturing and API manufacturing. The end product manufacturing segment held a largershare of the market in 2019. However, the API manufacturing segment is estimated to register a higherCAGR in the market during the forecast period.Rise in the number of pharmaceutical companies, technological advancements in continuous manufacturing systems and rise in the demand for pharmaceutical drugs are key drivers forthe growth of the end product manufacturing market.

End User-BasedInsights

Based on end user, the pharmaceutical continuous manufacturing market is segmented into full-scale manufacturing companies and R&D departments. The full-scale manufacturing companies segment held a largershare of the market in 2019. Also, the same segment is estimated to register a higherCAGR in the market during the forecast period.This is attributed to the increasing adoption of continuous technologies to address the challenges related to product quality, drug supply, and operational costs.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Pharmaceutical Continuous Manufacturing Market: Strategic Insights

pharmaceutical-continuous-manufacturing-market
Market Size Value inUS$ 1,459.53 Million in 2019
Market Size Value byUS$ 3,064.38 Million by 2027
Growth rateCAGR of 9.8% from 2020-2027
Forecast Period2020-2027
Base Year2020
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Partnerships and acquisitions are the mostcommonly adopted strategiesby companies to expand their footprints worldwide and meet the growing demand. The market players most commonly adopt these strategies in order to expand its product portfolio.

For instance, in May 2019, Thermo Fisher Scientific has acquired a drug substance-manufacturing site in Cork, Ireland, from GlaxoSmithKline to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredients (APIs).

Global Pharmaceutical Continuous Manufacturing Market – ByProduct

  • Integrated Systems
  • Semi-Continuous Systems
    • Continuous Granulators
    • Continuous Blenders
    • Continuous Compressors

    • Continuous Coaters
    • Continuous Dryers
    • Other Semi-Continuous Systems
  • Controls


Global Pharmaceutical Continuous Manufacturing Market – By Application

  • End Product Manufacturing
    • Solid Dosage Manufacturing
    • Liquid Dosage Manufacturing
  • API Manufacturing


Global Pharmaceutical Continuous Manufacturing Market – By End User

  • Full Scale Manufacturing Companies
    • Pharmaceutical Companies
    • Contract Manufacturing Organizations
  • R&D Departments
    • Contract Research Organizations
    • Research Institutes


Pharmaceutical Continuous ManufacturingMarket– By Geography

  • North America

    • US
    • Canada
    • Mexico
  • Europe

    • France
    • Germany
    • Italy
    • UK
    • Spain
  • Asia Pacific

    • China
    • India
    • South Korea
    • Japan
    • Australia
  • Middle East and Africa

    • South Africa
    • Saudi Arabia
    • UAE
  • South and Central America

    • Brazil
    • Argentina

Company Profiles

  • GEA Group
  • Thermo Fisher Scientific, Inc.
  • Glatt GmbH
  • Munson Machinery Co., Inc.
  • Hosokawa Micron Group
  • Coperion GmbH
  • Gericke AG
  • Powerex Corp
  • Freund-Vector Corporation
  • Fette Compacting
  • LEISTRITZ AG
  • KORSCH AG
  • ACG
  • Cadmach Machinery Co. Pvt. Ltd.
  • ALEXANDERWERK AG
  • Hovione
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Product ; Application ; End User and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


What is pharmaceutical continuous manufacturing?

Continuous Manufacturing technology is a method in which continuous development of products is involved to allow faster manufacturing with more productive and profitable products. The continuous manufacturing method in the pharmaceutical attributes to the production of an active component in a compressed unit with a high degree of automation. The market is driven by less time investment, less production cost, faster availability of reliable products in the market.

What are the driving factors for the pharmaceutical continuous manufacturing marketacross the globe?

The growth of the market is attributed to some key driving factors such as increasing shortage of medicines, and advantages offered by continuous manufacturing process. However, high capital costs required for the establishment of these systems expected to restraint the growth of the market during the forecast years.

What is the regional analysis in terms of pharmaceutical continuous manufacturing market?

Global pharmaceutical continuous manufacturing market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. In North America, the U.S. is the largest market for pharmaceutical continuous manufacturing. The federal government in the US and regulatory authorities are supportive towards transition from batch to continuous manufacturing of drugs and APIs which is leading to increasing number of companies and contract manufacturers adopting the techniques thereby leading to the market growth.The Asia Pacific region is expected to account for the fastest growth in the pharmaceutical continuous manufacturing market. In Japan and South Korea, the market is expected to grow owing to factors such as the large population countries such as China and India, increasing focus of market players towards Asian countries to open new production facilities in these regions, rising number of pharmaceutical companies.

The List of Companies - Pharmaceutical Continuous Manufacturing Market

  1. GEA Group
  2. Coperion GmbH
  3. Gericke AG
  4. Glatt GmbH
  5. Hosokawa Micron Group
  6. Munson Machinery Co. Inc.
  7. Powrex Corp
  8. Thermo Fisher Scientific Inc.
  9. Freund-vector Corporation
  10. Fette Compacting
  11. Alexanderwerk
  12. LEISTRITZ AG
  13. KORSCH AG
  14. ACG
  15. Cadmach Machinery Co. Pvt. Ltd.
  16. Hovioneen Aesica

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Pharmaceutical Continuous Manufacturing Market